Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response

References

• Anggård E, Gunne L-M, Holmstrand J, et al. (1975). Disposition of methadone in methadone maintenance. Clin Pharmacol Ther 17:258–266.
   PubMed Web of Science ®Google Scholar
• Anzenbacher P, Zanger UM. (2012) Metabolism of drugs and other xenobiotics. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA.
   Google Scholar
• Arima T, Motoyama Y, Yamamoto T, et al. (1977). Serum glycoproteins in the liver diseases. IV. Alpha-1 acid glycoprotein level in liver cirrhosis. Gastroenterol Jpn 12:43–46.
   PubMedGoogle Scholar
• Bart G, Walsh SL. (2013) Methadone pharmacodynamics and pharmacokinetics. In: Cruciani AR, Knotkova H, eds. Handbook of methadone prescribing and buprenorphine therapy. New York: Springer New York, 59–72.
   Google Scholar
• Bellward GD, Warren PM, Howald W, et al. (1977). Methadone maintenance: Effect of urinary pH on renal clearance in chronic high and low doses. Clin Pharmacol Ther 22:92–99.
   PubMed Web of Science ®Google Scholar
• Borowsky SA, Lieber CS. (1978). Interaction of methadone and ethanol metabolism. J Pharmacol Exp Ther 207:123–129.
   PubMed Web of Science ®Google Scholar
• Brunton LL, Chabner BA, Knollmann BC. (2011). Goodman & Gilman’s: The pharmacological basis of therapeutics. New York: McGraw-Hill – Medical Publishing Division.
   Google Scholar
• Bunten H, Liang WJ, Pounder D, et al. (2011). CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol 16:142–144.
   PubMed Web of Science ®Google Scholar
• Bunten H, Liang WJ, Pounder DJ, et al. (2010). OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther 88:383–389.
   PubMed Web of Science ®Google Scholar
• Bush E, Miller C, Friedman I. (2006). A case of serotonin syndrome and mutism associated with methadone. J Palliat Med 9:1257–1259.
   PubMed Web of Science ®Google Scholar
• Callahan RJ, Au JD, Paul M, et al. (2004). Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in Xenopus oocytes: Stereospecific and subunit effects. Anesth Analg 98:653–659.
   PubMed Web of Science ®Google Scholar
• Campbell SD, Crafford A, Williamson BL, Kharasch ED. (2013). Mechanism of autoinduction of methadone N-demethylation in human hepatocytes. Anesth Analg 117:52–60.
   PubMed Web of Science ®Google Scholar
• Carlquist JF, Moody DE, Knight S, et al. (2015). A possible mechanistic link between the CYP2C19 genotype, the methadone metabolite ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP), and methadone-induced corrected QT interval prolongation in a pilot study. Mol Diagn Ther 19:131–138.
   PubMed Web of Science ®Google Scholar
• Chang Y, Fang WB, Lin SN, Moody DE. (2011). Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: A reconciliation. Basic Clin. Pharmacol Toxicol 108:55–62.
   PubMed Web of Science ®Google Scholar
• Coleman MD. (2005) Human drug metabolism: An introduction. West Sussex, UK: John Wiley & Sons.
   Google Scholar
• Colombo S, Buclin T, Decosterd LA, et al. (2006). Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin Pharmacol Ther 80:307–318.
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, et al. (2005). Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593–604.
   PubMed Web of Science ®Google Scholar
• Davis CM, Fenimore DC. (1977). Methadone N-oxide in the Rhesus monkey. Journal of Pharm Pharmacol 29:573–574.
   PubMed Web of Science ®Google Scholar
• Deng Y, Bu Q, Hu Z, et al. (2012). (1) H-nuclear magnetic resonance-based metabonomic analysis of brain in Rhesus monkeys with morphine treatment and withdrawal intervention. J Neurosci Res 90:2154–2162.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2014a). [Licit and ilicit uses of medicines]. Acta Med Port 27:755–766.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2014b). Metabolomics of drugs of abuse: A more realistic view of the toxicological complexity. Bioanalysis 6:3155–3159.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2016a). Metabolomics of Δ(9)-tetrahydrocannabinol: Implications in toxicity. Drug Metabol Rev 48:80–87.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2016b). Oxidative and non-oxidative metabolomics of ethanol. Curr Drug Metabol 17:327–335.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ, Carvalho F, Duarte JA, et al. (2010). Collection of biological samples in forensic toxicology. Toxicol Mech Methods 20:363–414.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ, Magalhaes T. (2013). Forensic toxicology in drug-facilitated sexual assault. Toxicol Mech Methods 23:471–478.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ, Magalhaes T, Queiros O, et al. (2015). Signs and related mechanisms of ethanol hepatotoxicity. Curr Drug Abuse Rev 8:86–103.
   PubMedGoogle Scholar
• Dole VP, Kreek MJ. (1973). Methadone plasma level: Sustained by a reservoir of drug in tissue. Proc Natl Acad Sci USA 70:10.
   PubMed Web of Science ®Google Scholar
• Dole VP, Nyswander M. (1965). A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 193:646–650.
   PubMed Web of Science ®Google Scholar
• Eap CB, Buclin T, Baumann P. (2002). Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet 41:1153–1193.
   PubMed Web of Science ®Google Scholar
• Eap CB, Crettol S, Rougier JS, et al. (2007). Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 81:719–728.
   PubMed Web of Science ®Google Scholar
• Eap CB, Cuendet C, Baumann P. (1990a). Binding of d-methadone, 1-methadone, and dl-methadone to proteins in plasma of healthy volunteers: Role of the variants of α1-acid glycoprotein. Clin Pharmacol Ther 47:338–346.
   PubMed Web of Science ®Google Scholar
• Eap CB, Cuendet C, Baumann P. (1990b). Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. Clin Pharmacol Therap. 47:338–346.
   PubMed Web of Science ®Google Scholar
• Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. (2003). Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 3:CD002208.
   PubMedGoogle Scholar
• Ferrari A, Coccia CP, Bertolini A, Sternieri E. (2004). Methadone–metabolism, pharmacokinetics and interactions. Pharmacol Res 50:551–559.
   PubMed Web of Science ®Google Scholar
• Forcelli PA, Turner JR, Lee BG, et al. (2016). Anxiolytic- and antidepressant-like effects of the methadone metabolite 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP). Neuropharmacology 101:46–56.
   PubMed Web of Science ®Google Scholar
• Foster DJ, Somogyi AA, Bochner F. (1999). Methadone N-demethylation in human liver microsomes: Lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 47:403–412.
   PubMed Web of Science ®Google Scholar
• Gadel S, Crafford A, Regina K, Kharasch ED. (2013). Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6. Drug Metabol Dispos 41:709–713.
   PubMed Web of Science ®Google Scholar
• Garrido MJ, Aguirre C, Troconiz IF, et al. (2000). Alpha 1-acid glycoprotein (AAG) and serum protein binding of methadone in heroin addicts with abstinence syndrome. Int J Clin Pharmacol Ther 38:35–40.
   PubMed Web of Science ®Google Scholar
• Garrido MJ, Jiminez R, Gomez E, Calvo R. (1996). Influence of plasma-protein binding on analgesic effect of methadone in rats with spontaneous withdrawal. J Pharm Pharmacol 48:281–284.
   PubMed Web of Science ®Google Scholar
• Garrido MJ, Trocóniz IF. (1999). Methadone: A review of its pharmacokinetic/pharmacodynamic properties. J Pharmacol Toxicol Methods 42:61–66.
   PubMed Web of Science ®Google Scholar
• Gelston EA, Coller JK, Lopatko OV, et al. (2012). Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: A study using codeine in methadone- and buprenorphine-maintained subjects. Br J Clin Pharmacol 73:786–794.
   PubMed Web of Science ®Google Scholar
• Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, et al. (2001). Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metabol Dispos 29:242–251.
   PubMed Web of Science ®Google Scholar
• Gerber JG, Rhodes RJ, Gal J. (2004). Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16:36–44.
   PubMed Web of Science ®Google Scholar
• Gruber VA, McCance-Katz EF. (2010). Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep 7:152–160.
   PubMedGoogle Scholar
• Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. (2000). Methadone, ciprofloxacin, and adverse drug reactions. Lancet 356:2069–2070.
   PubMed Web of Science ®Google Scholar
• Horns WH, Rado M, Goldstein A. (1975). Plasma levels and symptom complaints in patients maintained on daily dosage of methadone hydrochloride. Clin Pharmacol Ther 17:636–649.
   PubMed Web of Science ®Google Scholar
• Inturrisi CE. (2005). Pharmacology of methadone and its isomers. Minerva Anestesiol 71:435–437.
   PubMedGoogle Scholar
• Inturrisi CE, Portenoy RK, Max MB, et al. (1990). Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. Clin Pharmacol Ther 47:565–577.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Yang W, Zhou Y, Ma L. (2003). Up-regulation of murine double minute clone 2 (MDM2) gene expression in rat brain after morphine, heroin, and cocaine administrations. Neurosci Lett 352:216–220.
   PubMed Web of Science ®Google Scholar
• Johnson BA. (2011) Addiction medicine: Science and practice. London: Springer.
   Google Scholar
• Katzung BG, Masters SB, Trevor AJ. (2012). Basic & clinical pharmacology. London, UK: McGraw-Hill Medical.
   Google Scholar
• Ketter TA, Flockhart DA, Post RM, et al. (1995). The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 15:387–398.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Hoffer C, Whittington D, Sheffels P. (2004). Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250–269.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Regina KJ, Blood J, Friedel C. (2015). Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism. Anesthesiology 123:1142–1153.
   PubMed Web of Science ®Google Scholar
• Klaassen CD. (2013). Casarett & Doull’s toxicology: The basic science of poisons. New York: McGraw-Hill.
   Google Scholar
• Kleykamp BA, Vandrey RG, Bigelow GE, et al. (2015). Effects of methadone plus alcohol on cognitive performance in methadone-maintained volunteers. Am J Drug Alcohol Abuse 41:251–256.
   PubMed Web of Science ®Google Scholar
• Krantz MJ, Martin J, Stimmel B, et al. (2009). QTc interval screening in methadone treatment. Ann Intern Med 150:387–395.
   PubMed Web of Science ®Google Scholar
• Kreek MJ. (1984). Opioid interactions with alcohol. Adv Alcohol Subst Abuse 3:35–46.
   PubMedGoogle Scholar
• Kreek MJ, Gutjahr CL, Garfield JW, et al. (1976). Drug interactions with methadone. Ann New York Acad Sci 281:350–371.
   PubMed Web of Science ®Google Scholar
• Kristensen K, Blemmer T, Angelo HR, et al. (1996). Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monit 18:221–227.
   PubMed Web of Science ®Google Scholar
• Kristensen K, Christensen CB, Christrup LL. (1995). The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 56:PL45–PL50.
   PubMed Web of Science ®Google Scholar
• Leonard BE. (2003) Fundamentals of psychopharmacology. West Sussex, UK: John Wiley & Sons.
   Google Scholar
• Levran O, Peles E, Hamon S, et al. (2013). CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol 18:709–716.
   PubMed Web of Science ®Google Scholar
• Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S. (2008). Interindividual variability of methadone response: Impact of genetic polymorphism. Mol Diagn Ther 12:109–124.
   PubMed Web of Science ®Google Scholar
• Lynn RK, Leger RM, Gerber N. (1976). Identification of glucuronide metabolites of d- and 1-methadone in bile from the isolated perfused rat liver. Res Commun Chem Pathol Pharmacol 15:1–10.
   PubMedGoogle Scholar
• Mannelli P, Patkar A, Rozen S, et al. (2009). Opioid use affects antioxidant activity and purine metabolism: Preliminary results. Hum Psychopharmacol 24:666–675.
   PubMed Web of Science ®Google Scholar
• Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. (2005). Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 95:915–918.
   PubMed Web of Science ®Google Scholar
• Martin WR. (1983). Pharmacology of opioids. Pharmacol Rev 35:283–323.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 3:CD002209.
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Jatlow P, Rainey PM. (2010). Effect of cocaine use on methadone pharmacokinetics in humans. Am J Addict 19:47–52.
   PubMed Web of Science ®Google Scholar
• Meemken L, Hanhoff N, Tseng A, et al. (2015). Drug-drug interactions with antiviral agents in people who inject drugs requiring substitution therapy. Ann Pharmacother 49:796–807.
   PubMed Web of Science ®Google Scholar
• Mendlik MT, Uritsky TJ. (2015). Treatment of neuropathic pain. Curr Treat Opt Neurol 17:50.
   PubMed Web of Science ®Google Scholar
• Meresaar U, Nilsson M-I, Holmstrand J, Änggård E. (1981). Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. Eur J Clin Pharmacol 20:473–478.
   PubMed Web of Science ®Google Scholar
• Mitchell TB, Dyer KR, Newcombe D, et al. (2004). Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. Br J Clin Pharmacol 58:609–617.
   PubMed Web of Science ®Google Scholar
• Moody DE. (2013). Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: Methadone and buprenorphine. Expert Opin Drug Metab Toxicol 9:675–697.
   PubMed Web of Science ®Google Scholar
• Moody DE, Alburges ME, Parker RJ, et al. (1997). The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos 25:1347–1353.
   PubMed Web of Science ®Google Scholar
• Nilsson M-I, Widerlöv E, Meresaar U, Änggård E. (1982a). Effect of urinary pH on the disposition of methadone in man. Eur J Clin Pharmacol 22:337–342.
   PubMed Web of Science ®Google Scholar
• Nilsson MI, Meresaar U, ÄNggård E. (1982b). Clinical pharmacokinetics of methadone. Acta Anaesthesiol Scand 26:66–69.
   Web of Science ®Google Scholar
• Oda Y, Kharasch ED. (2001). Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): Potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther 298:1021–1032.
   PubMed Web of Science ®Google Scholar
• Olsen GD. (1973). Methadone binding to human plasma proteins. Clin Pharmacol Ther 14:338–343.
   PubMed Web of Science ®Google Scholar
• Paine MF, Khalighi M, Fisher JM, et al. (1997). Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552–1562.
   PubMed Web of Science ®Google Scholar
• Paulozzi LJ, Ryan GW. (2006). Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prevent Med 31:506–511.
   PubMed Web of Science ®Google Scholar
• Perez de los Cobos J, Sinol N, Trujols J, et al. (2007). Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend 89:190–194.
   PubMed Web of Science ®Google Scholar
• Plummer JL, Gourlay GK, Cherry DA, Cousins MJ. (1988). Estimation of methadone clearance: Application in the management of cancer pain. Pain 33:313–322.
   PubMed Web of Science ®Google Scholar
• Pohland A, Boaz HE, Sullivan HR. (1971). Synthesis and identification of metabolites resulting from the biotransformation of DL-methadone in man and in the rat. J Med Chem 14:194–197.
   PubMed Web of Science ®Google Scholar
• Robinson SE, Maher JR, Wallace MJ, Kunko PM. (1997). Perinatal methadone exposure affects dopamine, norepinephrine, and serotonin in the weanling rat. Neurotoxicol Teratol 19:295–303.
   PubMed Web of Science ®Google Scholar
• Romach MK, Piafsky KM, Abel JG, et al. (1981). Methadone binding to orosomucoid (alpha 1-acid glycoprotein): Determinant of free fraction in plasma. Clin Pharmacol Ther 29:211–217.
   PubMed Web of Science ®Google Scholar
• Scott CC, Robbins EB, Chen KK. (1948). Pharmacologic comparison of the optical isomers of methadon. J Pharmacol Exp Ther 93:282–286.
   PubMed Web of Science ®Google Scholar
• Shiran MR, Lennard MS, Iqbal MZ, et al. (2009). Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 67:29–37.
   PubMed Web of Science ®Google Scholar
• Somogyi AA, Barratt DT, Ali RL, Coller JK. (2014). Pharmacogenomics of methadone maintenance treatment. Pharmacogenomics 15:1007–1027.
   PubMed Web of Science ®Google Scholar
• Sullivan HR, Due SL. (1973). Urinary metabolites of dl-methadone in maintenance subjects. J Med Chem 16:909–913.
   PubMed Web of Science ®Google Scholar
• Sullivan HR, Due SL, McMahon RE. (1972). The identification of three new metabolities of methadrone in man and in the rat. J Am Chem Soc 94:4050.
   PubMed Web of Science ®Google Scholar
• Sullivan HR, Due SL, McMahon RE. (1973). Letter: Methadone N-oxide in the urine of methadone maintenance subjects-an artifact? J Pharm Pharmacol 25:1009–1010.
   PubMed Web of Science ®Google Scholar
• Tian JN, Ho IK, Tsou HH, et al. (2012). UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients. Pharmacogenomics 13:879–888.
   PubMed Web of Science ®Google Scholar
• Totah RA, Allen KE, Sheffels P, et al. (2007). Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 321:389–399.
   PubMed Web of Science ®Google Scholar
• Totah RA, Sheffels P, Roberts T, et al. (2008). Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108:363–374.
   PubMed Web of Science ®Google Scholar
• Trescot AM, Helm S, Hansen H, et al. (2008). Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 11:S5–S62.
   PubMed Web of Science ®Google Scholar
• Tsai HJ, Wang SC, Liu SW, et al. (2014). Assessment of CYP450 genetic variability effect on methadone dose and tolerance. Pharmacogenomics 15:977–986.
   PubMed Web of Science ®Google Scholar
• Verebely K, Volavka J, Mulé S, Resnick R. (1975). Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 18:180–190.
   PubMed Web of Science ®Google Scholar
• Vos JW, Ufkes JGR, Wilgenburg H, et al. (1995). Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol 48:361–366.
   PubMed Web of Science ®Google Scholar
• Wang SC, Ho IK, Tsou HH, et al. (2013). Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort. OMICS 17:519–526.
   PubMed Web of Science ®Google Scholar
• Ward J, Bell J, Mattick RP, Hall W. (2012). Methadone maintenance therapy for opioid dependence. CNS Drugs 6:440–449.
   Web of Science ®Google Scholar
• Wu D, Otton SV, Sproule BA, et al. (1993). Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 35:30–34.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Smith RD, Caruso FS, Kellar KJ. (2001). Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs. J Pharmacol Exp Ther 299:366–371.
   PubMed Web of Science ®Google Scholar
• Yang HC, Chu SK, Huang CL, et al. (2016). Genome-wide pharmacogenomic study on methadone maintenance treatment identifies SNP rs17180299 and multiple haplotypes on CYP2B6, SPON1, and GSG1L associated with plasma concentrations of methadone R- and S-enantiomers in heroin-dependent patients. PLoS Genet 12:e1005910.
   PubMed Web of Science ®Google Scholar